S2B.WAR SYN2BIO SPÓŁKA AKCYJNA
- Market cap
- PLN 535M
- P/E
- -
- P/B
- 16.39x
- ROE
- -111.8%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is S2B.WAR undervalued?
Graham numberThe Graham number of SYN2BIO SPÓŁKA AKCYJNA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SYN2BIO SPÓŁKA AKCYJNA fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-111.8%), below 10%.
ROA 0/1
Return on assets (-83.0%) is below the industry median (-18.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-44.8%) is below the industry median (2.6%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.0%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.7 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (16.1x) is above the industry median (3.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
SYN2BIO SPÓŁKA AKCYJNA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SYN2BIO SPÓŁKA AKCYJNA
Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It is also engages in the research of new pharmaceutical compounds and its further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.
Full company profileSYN2BIO SPÓŁKA AKCYJNA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SYN2BIO SPÓŁKA AKCYJNA annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -14.0M | -19.9M | -28.9M | -45.5M |
| EBITDA | -13.5M | -19.6M | -28.3M | -44.9M |
| Net Income | -11.8M | -16.3M | -23.7M | -37.6M |
| EPS | -1.36 | -1.87 | -2.71 | -4.30 |
| Balance Sheet | ||||
| Total Assets | 14.0M | 20.2M | 26.2M | 45.3M |
| Total Liabilities | 2.53M | 1.35M | 9.53M | 11.7M |
| Shareholders' Equity | 11.4M | 18.8M | 16.7M | 33.6M |
| Cash & Short-term Investments | 5.98M | 7.06M | 7.22M | 19.0M |
| Cash Flow | ||||
| Operating Cash Flow | -13.5M | -20.7M | -20.2M | -27.7M |
| Capital Expenditure | 0.00 | 1.83M | 878K | 234K |
| Free Cash Flow | -13.5M | -22.5M | -21.1M | -28.0M |
| Ratios | ||||
| ROE | -103.7% | -86.7% | -141.9% | -111.8% |
| ROA | -84.9% | -80.9% | -90.3% | -83.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
SYN2BIO SPÓŁKA AKCYJNA dividends
SYN2BIO SPÓŁKA AKCYJNA has not paid dividends in the last 3 fiscal years.
Who owns SYN2BIO SPÓŁKA AKCYJNA
- Insiders 39.79%
- Institutions 8.48%
- Public & others 51.74%
- Shares outstanding 8.73M
SYN2BIO SPÓŁKA AKCYJNA company profile
- Company name
- SYN2BIO SPÓŁKA AKCYJNA
- Ticker
- S2B.WAR
- ISIN
- PLSNBIO00013
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- September
- Address
- ul. J. P. Dziekonskiego 3, Warsaw, Poland, 00-728
- Phone
- 48 223 27 09 10
- Website
- syn2bio.pl/en
About SYN2BIO SPÓŁKA AKCYJNA
Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It is also engages in the research of new pharmaceutical compounds and its further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.
SYN2BIO SPÓŁKA AKCYJNA management
3- Mr. Cezary Dariusz KozaneckiCEO & Chairman of the Management Board
- Ms. Anna SzymanskaMember of the Management Board
- Ms. Sawa Zuzanna ZarebinskaSecretary & Member of the Supervisory Board